GlaxoSmithKline

Despite headwinds, the techbio sector continues to attract significant investment and drive innovation, exemplified by the 2024 launch of Xaira, backed by over $1 billion, aiming to design novel therapeutic proteins using advanced AI. The sector is maturing through strategic consolidation, significant capital deployment, technical diversification, and steady clinical validation, as illustrated by 25 techbio organizations, including notable players like Isomorphic Labs, Generate:Biomedicines, Recursion Pharmaceuticals, and Schrödinger Inc., all leveraging AI for drug discovery. Emerging players such as Archon Biosciences, AION Labs, and Antiverse are also making strides, while established companies like Insilico Medicine and Ginkgo Bioworks continue to expand their platforms and partnerships.

GSK's DREAMM-7 trial shows belantamab mafodotin reduces death risk by 42% in multiple myeloma post-first relapse, with projected median OS of 84 months vs 51 months for daratumumab combination, and 3-year OS rate of 74% vs 60%. Therapy under regulatory review in seven major markets.

Muna Therapeutics partners with GSK to use MiND-MAP spatial multi-omics platform for Alzheimer’s drug target identification, receiving $35.2M upfront and potential $147.1M per target, aiming to transform neurodegenerative disease drug discovery.

Coauthors from UC San Diego, Columbia University, GSK, Scripps Research, Harvard, and other institutions collaborated on a study funded by the Bill and Melinda Gates Foundation, NIH, and National Institute for General Medical Sciences. The authors declare no competing interests.

Stefano Romeo's research identifies two types of steatotic liver disease: one aggressive, affecting the liver, and another linked to cardio-renal-metabolic syndrome. Genetic tests reveal 27 new variants, enabling risk score determination for tailored treatments. Parallel studies using unsupervised clustering confirm these findings, advancing precision medicine.

The phase III IMROZ trial found that adding isatuximab to bortezomib, lenalidomide, and dexamethasone (VRd) significantly reduced disease progression or death by 40% and doubled sustained MRD negativity rates in transplant-ineligible newly diagnosed multiple myeloma patients ≤ 80 years old, establishing isatuximab/VRd as a new standard of care.

NMPA accepted GSK's NDA for Blenrep (belantamab mafodotin) in combination with bortezomib plus dexamethasone for relapsed or refractory multiple myeloma, based on DREAMM-7 trial results showing significant efficacy, including overall survival. This marks the seventh major regulatory filing acceptance for belantamab mafodotin combinations this year.

The article discusses the importance of enabling JavaScript for optimal app performance.

Nuvalent appoints Grant Bogle to its Board of Directors, enhancing its transition from development to commercialization of novel kinase inhibitors, with pivotal data expected in 2025.